Results 121 to 130 of about 2,106 (155)
Some of the next articles are maybe not open access.
An Overview of the Pharmacokinetic Disposition of Darbepoetin alfa
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002Darbepoetin alfa is a new erythropoiesis‐stimulating protein that has five carbohydrate chains compared with three in recombinant human erythropoietin (r‐HuEPO, epoetin alfa). Owing to its increased carbohydrate content, the terminal half‐life of darbepoetin alfa is 2–3‐fold greater than that of r‐HuEPO in patients with chronic kidney disease or cancer.
William C, Zamboni, Clinton E, Stewart
openaire +2 more sources
Darbepoetin Alfa and History of Thromboembolic Events
Journal of Clinical Oncology, 2009TO THE EDITOR: In their pooled analysis of individual patientlevel data from all randomized double-blind placebo-controlled trials in patients with chemotherapy-induced anemia receiving darbopoetin alfa or placebo, Ludwig et al do not report whether the proportion of patients with a history of thromboembolic events was well balanced between the two ...
Ferretti G., Felici A., Cognetti F.
openaire +1 more source
Darbepoetin alfa for anemia with myelodysplastic syndrome
Expert Review of Hematology, 2015The myelodysplastic syndromes are characterized by refractory cytopenias that lead to symptomatic anemia, bleeding, and increased risk for infections. For almost two decades, the use of darbepoetin and other erythropoietin stimulating agents to treat symptomatic anemia in lower-risk myelodysplastic syndromes has been a standard of care.
David J, Seastone, Aaron T, Gerds
openaire +2 more sources
BioDrugs, 2005
Darbepoetin alfa (Aranesp), Nespo) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is characterized by delayed clearance and a more prolonged elimination ...
Dean M, Robinson, Stephanie E, Easthope
openaire +2 more sources
Darbepoetin alfa (Aranesp), Nespo) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is characterized by delayed clearance and a more prolonged elimination ...
Dean M, Robinson, Stephanie E, Easthope
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2002
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of anemia associated with renal disease. The drug was approved by the European Commission in June 2001, under the tradename Aranesp, for the treatment of anemia in chronic kidney failure including patients on and not yet on ...
F, Locatelli, L D, Vecchio
openaire +1 more source
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of anemia associated with renal disease. The drug was approved by the European Commission in June 2001, under the tradename Aranesp, for the treatment of anemia in chronic kidney failure including patients on and not yet on ...
F, Locatelli, L D, Vecchio
openaire +1 more source
Darbepoetin alfa (Aranesp™) in children with chronic renal failure
Kidney International, 2005Denis F Geary +2 more
exaly